Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Lerer

Showing results (11-20 of 147) with videos related to

Pageof 15
Sort By:
Harefuah|February 24, 2011
[The use of thyroid hormones in the treatment of depression]Rena Cooper, Bernard Lerer
The International Journal of Neuropsychopharmacology|October 9, 2002
Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directionsBernard Lerer, Fabio Macciardi
Convulsive Therapy|January 1, 1986
Optimum Frequency of Electroconvulsive Therapy: Implications for Practice and ResearchBernard Lerer, Baruch Shapira
Convulsive Therapy|January 1, 1989
Implications of Clinical Spectrum for Mechanisms of Action: ECT and Antidepressants ReconsideredPesach Lichtenberg, Bernard Lerer
The International Journal of Neuropsychopharmacology|December 1, 2007
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitorsRena Cooper-Kazaz, Bernard Lerer
Dialogues in Clinical Neuroscience|April 28, 2006
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementationBernard Lerer, Ronnen H Segman
Molecular Psychiatry|November 9, 2023
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disordersUriel Heresco-Levy, Bernard Lerer
Convulsive Therapy|January 1, 1988
Medication Outcome in ECT-Resistant DepressionBaruch Shapira, Seth Kindler, Bernard Lerer
The International Journal of Neuropsychopharmacology|April 3, 2001
Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical reviewMichael E. Newman, Baruch Shapira, Bernard Lerer
Journal of Clinical Psychopharmacology|June 4, 2010
Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronineRena Cooper-Kazaz, Aviva Cohen, Bernard Lerer
Pageof 15

Showing results (11-20 of 147) with videos related to

Sort By:
Pageof 15
Harefuah|February 24, 2011
[The use of thyroid hormones in the treatment of depression]Rena Cooper, Bernard Lerer
The International Journal of Neuropsychopharmacology|October 9, 2002
Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directionsBernard Lerer, Fabio Macciardi
Convulsive Therapy|January 1, 1986
Optimum Frequency of Electroconvulsive Therapy: Implications for Practice and ResearchBernard Lerer, Baruch Shapira
Convulsive Therapy|January 1, 1989
Implications of Clinical Spectrum for Mechanisms of Action: ECT and Antidepressants ReconsideredPesach Lichtenberg, Bernard Lerer
The International Journal of Neuropsychopharmacology|December 1, 2007
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitorsRena Cooper-Kazaz, Bernard Lerer
Dialogues in Clinical Neuroscience|April 28, 2006
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementationBernard Lerer, Ronnen H Segman
Molecular Psychiatry|November 9, 2023
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disordersUriel Heresco-Levy, Bernard Lerer
Convulsive Therapy|January 1, 1988
Medication Outcome in ECT-Resistant DepressionBaruch Shapira, Seth Kindler, Bernard Lerer
The International Journal of Neuropsychopharmacology|April 3, 2001
Evaluation of central serotonergic function in affective and related disorders by the fenfluramine challenge test: a critical reviewMichael E. Newman, Baruch Shapira, Bernard Lerer
Journal of Clinical Psychopharmacology|June 4, 2010
Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronineRena Cooper-Kazaz, Aviva Cohen, Bernard Lerer
Pageof 15